https://numinus.ca/ Numinus Wellness Inc. (NUMI Stock Report) is the latest entrant to the list of mushroom penny stocks to watch. The company IPOd on May 20th opening at $1CAD. The company went public via a reverse take over, and was formerly Rojo Resources. What’s also of note is that In connection with the Transaction, on March 3, 2020, the company closed a non-brokered private placement of 22,980,000 subscription receipts at a price of $0.25 per Subscription Receipt for gross proceeds of $5,745,000. Needless to say, NUMI stock has taken off on May 20 in light of the recent sector hype. Numinus offers psychedelic treatments, however, psychedelic therapies are not currently available at our Vancouver center. The company has said that “Once approved by Health Canada and various Colleges, our centre will be ideal places for psychedelic therapies to take place in a safe, controlled therapeutic environment.” However, during this waiting period, Numinus is tapping its other operating pillars that include Numinus Bioscience and Numinus R&D. Numinus was issued a dealer’s license under the Controlled Substances Act in July 2019. Its Numinus Bioscience specifically, is licensed by Health Canada to test, sell, distribute, and eventually conduct research on psychedelic substances. The biggest question right now is will NUMI stock psych-out investors with the discounted shares or will it ease early concerns and move to new highs before the end of the week?
Licensed by Health Canada to test, sell and distribute psychedelic substances.
Numinus is at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness.
Through Numinus Bioscience (in alignment with licence holder Salvation Botanicals Ltd), Numinus has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Numinus is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances.
Numinus also operates a stand-alone centre offering patients integrative health solutions. A purpose-built facility is planned for Vancouver in 2021.